Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Salim Virani, MD"'
Autor:
Allan Zhang, BA, Ramsey Kalil, MD, Alexander Marzec, MD, Stephanie A. Coulter, MD, Salim Virani, MD, Kershaw V. Patel, MD, MSCS, Matthew W. Segar, MD, MS
Publikováno v:
Texas Heart Institute Journal, Vol 51, Iss 1, Pp 1-10 (2024)
Patients with type 2 diabetes face an elevated risk of cardiovascular disease. This review centers on sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of drugs that, according to a growing body of evidence, may have major potential for mana
Externí odkaz:
https://doaj.org/article/501801881d63483986cc157c6ca7b2af
Autor:
Athena L. Huang, MD, Ann Marie Navar, MD, PhD, Colby Ayers, MS, Anand Rohatgi, MD, MSCS, Erin Michos, MD, MHS, Salim Virani, MD, PhD, Parag Joshi, MD, MHS, Eric Peterson, MD, MPH, Amit Khera, MD, MSc
Publikováno v:
American Journal of Preventive Cardiology, Vol 15, Iss , Pp 100563- (2023)
Therapeutic Area: CVD Prevention – Primary and Secondary Background: Aspirin for the primary prevention of cardiovascular disease (CVD) remains controversial. The 2022 US Preventive Services Task Force (USPSTF) guidelines give a grade C recommendat
Externí odkaz:
https://doaj.org/article/dc4b1827fff641a5b2590293e312ef51
Autor:
June K. Pickett, MD, Maulin Shah, MD, Michael Gillette, PharmD, Peter Jones, MD, Salim Virani, MD, PhD, Christie Ballantyne, MD, Vijay Nambi, MD, PhD
Publikováno v:
JACC: Case Reports, Vol 2, Iss 7, Pp 1042-1045 (2020)
A 72-year-old man with coronary artery disease, statin intolerance, and chronic kidney disease stage IIIa was initiated on alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, and developed acute kidney injury. A kidney biopsy was p
Externí odkaz:
https://doaj.org/article/e5f5aad93cdf4f85b6181b3f8f3a85ef